FDA Brief

Warning letters Drugs

FDA warning letter to

Nature’s Innovation, Inc.

High riskIssued Aug 18, 2023Posted Aug 22, 2023Center for Drug Evaluation and Research | CDER

FDA warned Nature’s Innovation over unapproved drugs marketed for molluscum and shingles, including a kit for children.

What happened

In July 2023, FDA reviewed www.naturasil.com and the company’s Instagram and Facebook pages, which direct consumers to the website to buy products. FDA found the Naturasil Molluscum Treatment Kit and Naturasil Shingles offered for sale with claims to treat molluscum contagiosum and shingles. FDA said these are unapproved new drugs (products needing FDA approval before sale) because no FDA-approved application is in effect for them.

What FDA found

  1. FDA says the products are drugs because the website and social media claim they treat molluscum and shingles.

    section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)
  2. FDA says the products are “new drugs” (drugs that need FDA approval before sale) because they are not generally recognized as safe and effective for these uses.

    section 201(p) of the FD&C Act, 21 U.S.C. 321(p)
  3. FDA says the company sells the products without an FDA-approved application, which the law requires for new drugs.

    sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a)
  4. FDA says labeling the products “homeopathic” does not exempt them, and ingredients promoted on the website count as active ingredients under FDA rules.

    21 C.F.R. 201.66(b)(2)

What FDA wants

FDA tells the company to notify it in writing within 15 working days of the steps taken to correct the violations, explain how recurrence will be prevented, and include related documentation. If the company believes the products are not in violation, it must include its reasoning and supporting information.

Who should pay attention

  • Companies selling “natural” remedies with disease-treatment claims
  • Retailers and online marketplaces listing Naturasil products
  • Brands marketing products for children or for shingles

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk